Drug Profile
Research programme: AZM 140 - Acambis/Alizyme
Alternative Names: AZM 140 research programme - Acambis/AlizymeLatest Information Update: 16 Jul 1999
Price :
$50
*
At a glance
- Originator Acambis; Alizyme
- Class
- Mechanism of Action Amylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 1999 Discontinued-Preclinical for Obesity in United Kingdom (Unknown route)
- 16 Jul 1999 Discontinued-Preclinical for Type-2 diabetes mellitus in United Kingdom (Unknown route)
- 04 Jun 1997 Preclinical development for Obesity in United Kingdom (Unknown route)